TOP TEN perturbations for 1553395_a_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553395_a_at
Selected probe(set): 1553395_a_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553395_a_at (1553395_a_at) across 6672 perturbations tested by GENEVESTIGATOR:

IL-4; GM-CSF study 1 (late) / untreated monocyte sample

Relative Expression (log2-ratio):3.778082
Number of Samples:6 / 12
Experimental IL-4; GM-CSF study 1 (late)
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 5 days. Cytokine treatment was repeated at day 3.
Control untreated monocyte sample
Freshly isolated human monocytes from healthy donors.

TNF-ɑ; IL-1b; IL-6; PGE2 study 1 / control antibody treated immature dendritic cell sample

Relative Expression (log2-ratio):-3.219739
Number of Samples:4 / 5
Experimental TNF-ɑ; IL-1b; IL-6; PGE2 study 1
Immature dendritic cells (DCs) treated with inflammatory cytokine cocktail (10 ng/ml IL-1b, 1,000 U/ml IL-6, 10 ng/ml TNF-ɑ, 1μg/ml prostaglandin E2) for 24 h.
Control control antibody treated immature dendritic cell sample
Immature dendritic cells (DCs) treated with isotype control antibody (10 - 20μg/ml mouse IgG1 isotype) for 24 h.

bronchial epithelial cell differentiation study 1 (day28) / bronchial epithelial cell differentiation study 1 (confluent)

Relative Expression (log2-ratio):2.9936867
Number of Samples:3 / 3
Experimental bronchial epithelial cell differentiation study 1 (day28)
Differentiated normal human bronchial epithelial cell (NHBE) cultured for 28 days in an air-liquid interface (ALI) system. At this time point cells were fully differentiated and formed a polarized, pseudostratified mucociliary epithelium. In order to generate the ALI culture, undifferentiated cells were grown under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. When cells reached confluency (after 3-5 days), an air-liquid interface culture (ALI system) was created by removing the apical medium and replacing the medium of the basal compartment with B-ALI differentiation medium. During the 28 days culture medium was replaced every 48 hour.
Control bronchial epithelial cell differentiation study 1 (confluent)
Confluent undifferentiated normal human bronchial epithelial cell (NHBE) cultured for 3-5 days under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. At this time point cells formed a monolayer covering the whole surface of the insert.

bronchial epithelial cell differentiation study 1 (day28) / bronchial epithelial cell differentiation study 1 (subconfluent)

Relative Expression (log2-ratio):2.9464102
Number of Samples:3 / 3
Experimental bronchial epithelial cell differentiation study 1 (day28)
Differentiated normal human bronchial epithelial cell (NHBE) cultured for 28 days in an air-liquid interface (ALI) system. At this time point cells were fully differentiated and formed a polarized, pseudostratified mucociliary epithelium. In order to generate the ALI culture, undifferentiated cells were grown under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. When cells reached confluency (after 3-5 days), an air-liquid interface culture (ALI system) was created by removing the apical medium and replacing the medium of the basal compartment with B-ALI differentiation medium. During the 28 days culture medium was replaced every 48 hour.
Control bronchial epithelial cell differentiation study 1 (subconfluent)
Subconfluent undifferentiated normal human bronchial epithelial cell (NHBE) cultured for 1-2 days under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. At this time point cells still grew dispersed in the culture insert and covered 70% of the insert.

IL-4; GM-CSF study 1 (intermediate) / untreated monocyte sample

Relative Expression (log2-ratio):2.90207
Number of Samples:7 / 12
Experimental IL-4; GM-CSF study 1 (intermediate)
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 24 hours.
Control untreated monocyte sample
Freshly isolated human monocytes from healthy donors.

dendritic cell study 1 (LPS; mdDC) / dendritic cell study 1 (mdDC)

Relative Expression (log2-ratio):-2.7003202
Number of Samples:6 / 6
Experimental dendritic cell study 1 (LPS; mdDC)
Monocyte-derived dendritic cells (mdDC) harvested after 6 days of differentiation with GM-CSF and IL-4 and 3 days of stimulation with LPS. CD14+ monocytes were isolated from peripheral blood of healthy donors by magnetic separation and cultured in RPMI-10 medium with 50 ng/ml GM-CSF and 25 ng/ml IL-4 for dendritic cell differentiation. Starting from day 6, cells were exposed to 1 mg/ml lipopolysaccharide (LPS) for 3 days. On day 9, cells were harvested and sorted by flow cytometry using the following markers: CD14-/CD209+.
Control dendritic cell study 1 (mdDC)
Monocyte-derived dendritic cells (mdDC) harvested after 6 days of differentiation with GM-CSF and IL-4. CD14+ monocytes were isolated from peripheral blood of healthy donors by magnetic separation and cultured in RPMI-10 medium with 50 ng/ml GM-CSF and 25 ng/ml IL-4 for dendritic cell differentiation. After 6 days, cells were harvested and sorted by flow cytometry using the following markers: CD14-/CD209+.

Langerhans cell histiocytosis study 2 (multifocal) / Langerhans cell histiocytosis study 2 (unifocal)

Relative Expression (log2-ratio):-2.3413944
Number of Samples:2 / 8
Experimental Langerhans cell histiocytosis study 2 (multifocal)
Langerhans cell histiocytes (LCH, CD207+) samples isolated from LCH lesions of patients with multifocal (bone, skin lesions) disease.
Control Langerhans cell histiocytosis study 2 (unifocal)
Langerhans cell histiocytes (LCH, CD207+) samples isolated from LCH lesions of patients with unifocal, single system disease (bone lesion).

T-cell activation study 1 / quiescent CD4+ T-cell sample

Relative Expression (log2-ratio):-2.2859545
Number of Samples:2 / 2
Experimental T-cell activation study 1
CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 1 day.
Control quiescent CD4+ T-cell sample
Quiescent CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors.

cutaneous T-cell lymphoma study 1 (tumor phase) / normal skin tissue

Relative Expression (log2-ratio):2.1632843
Number of Samples:4 / 8
Experimental cutaneous T-cell lymphoma study 1 (tumor phase)
Lesional skin biopsies from patients with cutaneous T-cell lymphoma in the tumor phase (extranodal).
Control normal skin tissue
Skin biopsies from healthy individuals.

T-cell activation study 2 / quiescent CD4+ T-cell sample

Relative Expression (log2-ratio):-2.1019182
Number of Samples:2 / 2
Experimental T-cell activation study 2
CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 2 days..
Control quiescent CD4+ T-cell sample
Quiescent CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors.